Cipla is on track to launch key products, such as gAdvair, gAbraxane, gRevlimid and three peptide products over FY23-24, it said, adding that the US sales run-rate will improve from H2FY23, and barring COVID-19, sales performance in India continues to be robust. The brokerage firm expects a revenue CAGR of 13 per cent, an EBITDA CAGR of 21 per cent and a PAT CAGR of 28 per cent over FY22-24E.
Multibaggers: 15 Smallcap stocks surge up to 225% in just 3 months. Are they in your Portfolio?
Despite a weak BSE Smallcap Index, 23 small-cap stocks surged 50%–225% in three months, with 15 delivering over 60% gains, highlighting strong returns even in
October 8, 2025